Skip to main content

ADVERTISEMENT

lymphoma

Conference Coverage
12/03/2020
Journal of Clinical Pathways
Real-World Analysis of Outpatient Rasburicase to Prevent and Manage Tumor Lysis Syndrome in Newly Diagnosed Adults With Leukemia or Lymphoma
Research Reports
03/16/2020
Scott C Howard, MD, MSc
Alex R Cockerham, PharmD, RPh, MSc
Edward Drea, PharmD
Yvonne Barnes, DNP, RN
Michael Ryan
William Irish, PhD
Lucio Gordan, MD
Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...
Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...
...
03/16/2020
Journal of Clinical Pathways
Research in Review
02/13/2017
JCP Editors
Patients with an age-related blood condition undergoing autologous stem cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, reports a new study published in the Journal of Clinical...
Patients with an age-related blood condition undergoing autologous stem cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, reports a new study published in the Journal of Clinical...
...
02/13/2017
Journal of Clinical Pathways
Research in Review
01/13/2017
JCP Editors
Patients with an age-related blood condition undergoing autologous stem-cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, says a new study published in the Journal of Clinical...
Patients with an age-related blood condition undergoing autologous stem-cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, says a new study published in the Journal of Clinical...
...
01/13/2017
Journal of Clinical Pathways
Research in Review
12/14/2015
JCP Editors
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
...
12/14/2015
Journal of Clinical Pathways
Research in Review
12/10/2015
JCP Editors
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
...
12/10/2015
Journal of Clinical Pathways